Week in Review: Fosun Signs $125 Million Deal for Ardelyx IBS Treatment

Deals and Financings Fosun Pharma entered a $125 million agreement for China rights to tenapanor, an Ardelyx treatment for irritable bowel syndrome with constipation; Sinopharm Capital, a PE fund started by Sinopharm Group, was a co-lead in an $18 million financing of Virtual Incision, a Nebraska medical device company; Clover Biopharma of Chengdu completed a $9.5 million Series A financing led by Tianhe Life Sciences Venture Fund for its biologic/biosimilar portfolio; BGI Genomics announced a $7.6 million joint venture with Kangmei Pharma that will apply gene sequencing to TCM products; Trials and Approvals Hutchison China MediTech (Chi-Med) announced the start of a US Phase I bridging trial of its lead drug, fruquintinib, in patients with solid tumor cancer. Stock Symbols: (SHA: 600196; HK: 2196) (NSDQ: ARDX) (SHZ: 300676) (SHA: 600518) (AIM/NSDQ: HCM) Share this with colleagues: // //